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Original ArticleCSF Rhinorrhea After Endonasal Intervention to the Skull Base (CRANIAL) — Part 2:
Impact of COVID-19CRANIAL Consortium-BACKGROUND: During the coronavirus disease 2019
(COVID-19) pandemic, concerns have been raised regarding
the increased risk of perioperative mortality for patients
with COVID-19, and the transmission risk to healthcare
workers, especially during endonasal neurosurgical
operations. The Pituitary Society has produced recom-
mendations to guide management during this era. We
sought to assess contemporary neurosurgical practice and
the effects of COVID-19.
-METHODS: A multicenter prospective observational
cohort study was conducted at 12 tertiary neurosurgical
units (United Kingdom and Ireland). Data were collected
from March 23 to July 31, 2020, inclusive. The data points
collected included patient demographics, preoperative
COVID-19 test results, operative modifications, and 30-day
COVID-19 infection rates.
-RESULTS: A total of 124 patients were included. Of the
124 patients, 116 (94%) had undergone COVID-19 testing
preoperatively (transsphenoidal approach, 97 of 105 [92%];
expanded endoscopic endonasal approach, 19 of 19
[100%]). One patient (1 of 116 [0.9%]) had tested positive for
COVID-19 preoperatively, requiring a delay in surgery until
the infection had been confirmed as resolved. Other than
transient diabetes insipidus, no other complications were
reported for this patient. All operating room staff had wornKey words
- Cerebrospinal fluid leak




- Skull base surgery
Abbreviations and Acronyms
CI: Confidence interval
COVID-19: Coronavirus disease 2019
CRANIAL: CSF rhinorrhea after endonasal intervention to the skull base
CSF: Cerebrospinal fluid
EEA: Expanded endoscopic endonasal approach
HCW: Healthcare worker
PPE: Personal protective equipment
e1090 www.SCIENCEDIRECT.com WORLD NEat least level 2 personal protective equipment. Adapta-
tions to surgical techniques included minimizing drilling,
draping modifications, and the use of a nasal iodine
wash. At 30 days postoperatively, no evidence of COVID-19
infection (symptoms or positive formal testing
results) were found in our cohort and no mortality had
occurred.
-CONCLUSIONS: Preoperative screening protocols and
operative modifications have facilitated endonasal neuro-
surgery during the COVID-19 pandemic, with the Pituitary
Society guidelines followed for most of these operations.
We found no evidence of COVID-19 infection in our cohort
and no mortality, supporting the use of risk mitigation
strategies to continue endonasal neurosurgery in subse-
quent pandemic waves.INTRODUCTIONhe coronavirus disease 2019 (COVID-19) pandemic is an
ongoing global pandemic caused by a novel coronavirusT(severe acute respiratory syndrome coronavirus 2 [SARS-
CoV-2]).1,2 Measures were enacted to mitigate the spread of the
virus and, thereby, prevent national healthcare systems from
being overwhelmed. These measures included reenlisting retiredSARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
TSA: Transsphenoidal approach
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specialty care.4,5 As a secondary consequence of this reallocation
of resources in healthcare services globally, it proved
increasingly challenging to continue providing existing services
for other diseases and conditions, including a noticeable
reduction in surgical activity.6-8 This reduction was likely com-
pounded by the initial concern that patients undergoing surgery
would be an especially vulnerable group owing to their risk of
exposure9 and, as such, a more cautious approach was taken
regarding surgery.
One such specialty that has seen their normal services dis-
rupted is neurosurgery,10 with some countries reporting the
cancellation of more than one half of all their indicated
neurosurgical operations.11 This has been especially so for
pituitary surgery.12,13 One factor that played a role in the
reduction of pituitary surgery was the need to protect healthcare
workers (HCWs).10,12 The transmission of the SARS-CoV-2 virus
occurs primarily via large respiratory droplets containing the
virus. Therefore, HCWs working in certain specialties and sub-
specialties were considered to have a high risk owing to their
frequent exposure to oronasal secretions.14 These HCWs include
those involved in pituitary surgery, given the number of
procedures for which access is via the nasal cavity and sphenoid
sinus.15 To manage the risk to HCWs involved in such
procedures, the Professional Education Committee of the
Pituitary Society produced a set of comprehensive guidelines for
international guidance.12 These included advising all patients to
undergo COVID-19 screening preoperatively, the use of non-
drill techniques, considerations for alternative approaches (e.g.,
transcranial), and for operating room staff involved in endoscopic
or microscopic endonasal approach surgeries to wear at least level
2 personal protective equipment (PPE).16,17
Although the caseloads in neurosurgery have decreased, some
operations have been performed during the course of the
pandemic.18,19 These operations were most likely performed for
patients requiring urgent or emergency surgery,20 including
patients presenting with pituitary apoplexy, visual loss,
malignant pathology, or significant endocrine disorders.
However, reported data are lacking regarding the number of
neurosurgical operations performed, their indications, and the
postoperative complications for the patients who had undergone
neurosurgical operations during the COVID-19 pandemic. These
data are essential, especially to quantify the effects on those who
have undergone an endonasal operation in the context of a res-
piratory virus. The timeline of a prospective multicenter pilot study
in the United Kingdom and Republic of Ireland—CRANIAL (CSF
[cerebrospinal fluid] rhinorrhea after endonasal intervention to
the skull base)21—coincided with the start of the COVID-19
pandemic. This provided a unique opportunity to assess the ef-
fects of the COVID-19 pandemic on endonasal surgery practices in
the United Kingdom in real time. Therefore, in the present report,
our primary aim was to determine whether the advice regarding
COVID-19 testing and the use of PPE had been followed, and to
investigate the intraoperative adaptations used to minimize the
risk of COVID-19, the 30-day postoperative COVID-19 infection
rate, and the mortality rate.WORLD NEUROSURGERY 149: e1090-e1097, MAY 2021METHODS
Study Design
A multicenter prospective observational cohort study design was
implemented21 at 12 tertiary academic neurosurgical units where
the CRANIAL network had previously been established:
Aberdeen Royal Infirmary (Aberdeen, United Kingdom),
Addenbrooke’s Hospital (Cambridge, United Kingdom),
Beaumont Hospital (Dublin, Ireland), Greater Manchester
Neurosciences Centre (Salford, United Kingdom), John Radcliffe
Hospital (Oxford, United Kingdom), National Hospital for
Neurology and Neurosurgery (London, United Kingdom), Queen
Elizabeth Hospital Birmingham (Birmingham, United Kingdom),
Royal Hallamshire Hospital (Sheffield, United Kingdom), Royal
Victoria Hospital (Belfast, United Kingdom), Royal Victoria
Infirmary (Newcastle-upon-Tyne, United Kingdom), Sheffield
Children’s Hospital (Sheffield, United Kingdom), and the
Walton Centre (Liverpool, United Kingdom). The project was
registered as a service evaluation at each center, with approval
received from the audit department of each institution (and
Caldicott guardians when required). The local team consisted of
consultant lead(s) with overall project responsibility, trainee
lead(s) in charge of data collection, and, on occasion, student
lead(s) for additional support. The STROBE (strengthening the
reporting of observational studies in epidemiology) statement
was used in the preparation of this report.22
The eligible cases included patients of all ages who had un-
dergone the transsphenoidal approach (TSA) for sellar tumors or
the expanded endonasal approach (EEA) for skull base tumors.21
The exclusion criteria were transcranial surgery and a history of
preoperative CSF rhinorrhea. Case selection was limited to
patients who had presented from March 23 to July 31, 2020,
inclusive. Before March 23, 2020, pauses had occurred in data
collection owing to data pro forma amendments and attaining
additional approvals (e.g., information governance approvals
where requested). This also allowed for our data to coincide
with when the first lockdown had begun in the United Kingdom.23Data Collection
The data points collected included the patient demographics,
preoperative COVID-19 status, operative modifications, and
postoperative COVID-19 data. The primary outcomes of interest
were as follows: 1) the COVID-19 preoperative screening method
used; 2) the precautions taken to reduce the risk of airborne
pathogen transmission; and 3) the 30-day COVID-19 infection rate
for patients postoperatively. The secondary outcomes of interest
were the length of hospital stay and the mortality rate.
The local teams submitted data to a secure web-based central
database hosted by Castor Electronic Data Capture (Amsterdam,
The Netherlands; available at: https://www.castoredc.com/). All
initial data were collected within 30 days of surgery, followed by a
30-day follow-up window. The data points collected by medical
students or junior trainees were confirmed with the operating
surgeons or senior members of the team before final submission
to the Castor Electronic Data Capture system.21www.journals.elsevier.com/world-neurosurgery e1091




Total patients 102 22 124
Sex
Male 54 11 65
Female 48 11 59
BMI (kg/m2)
>30 29 3 32
<30 67 19 86
Visual loss
Yes 69 14 83
No 30 8 38
Anterior pituitary deficiency requiring
hydrocortisone preoperatively
25 5 30
Posterior pituitary deficiency requiring
desmopressin preoperatively
4 1 5
TSA, transsphenoidal approach; EEA, expanded endonasal approach; BMI, body mass
index.
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Data validation was performed in all centers to audit quantitative
data accuracy.21 This involved an independent data validator (who
had not collected the local data) who reviewed the datasets for
several enrolled cases, selected randomly. Each data validator
was from the hospital in which the data had been collected. The
targets for validation were a secure and accurate record of the
Castor identification records with corresponding medical
record numbers, no case or data duplication, and data accuracy
of >95%.
Statistical Analysis
The pooled quantitative data were analyzed using Microsoft Excel,
version 16.41 (Microsoft, Redmond, Washington, USA), to present
descriptive statistics. If a data point was missing from a case, the
denominator was adjusted to account for the missing data. The
data were used to create tables summarizing the demographic
characteristics, tumor characteristics, operative characteristics,
and methods used to reduce COVID-19 transmission. For 3 cen-
ters, data were available before the lockdown had begun
(November 1, 2019 to March 22, 2020). The Mann-Whitney U test
was used for comparative analysis (pre-lockdown vs. during
lockdown) of patient age and hospital length of stay for the pa-
tients from these 3 centers. The Fisher exact test was for
comparative analysis (pre-lockdown vs. during lockdown) of the
remaining data points for patients from these 3 centers. Statistical
analysis was performed using Prism, version 5 (GraphPad,




Data were collected for 124 patients across the 12 tertiary neuro-
surgical centers. The neurosurgical centers had contributed data
for 2 to 21 patients. No duplicates in the cases or data were found
in the records audited for data validation. All centers had fulfilled
the >95% accuracy target per case.
Patient Characteristics
The median patient age in the present study was 50.5 years (range,
7e82 years). Of the 124 patients, 65 were male and 59 were female.
At presentation, the body mass index had been recorded for 118
patients (95%). Of these 118 patients, 32 (27%) had had a body
mass index >30 kg/m2 (29 of 96 in the TSA group [30%] and 3 of
22 in the EEA group [14%]). The patient’s vision at presentation
had been recorded for 121 of the 124 patients (98%). Visual loss
(acuity and/or field deficits) was present in 83 of these 121 patients
(69%) preoperatively (TSA, 69 of 99 [70%]; EEA, 14 of 22 [64%]).
Of the 124 patients, 30 (24%) had presented with anterior pituitary
deficiency requiring hydrocortisone therapy preoperatively (TSA,
25 of 102 [25%]; EEA, 5 of 22 [23%]). Five patients (4%) had had
posterior pituitary deficiency requiring desmopressin preopera-
tively (TSA, 4 of 102 [4%]; EEA, 1 of 22 [5%]). These data are
summarized in Table 1. Comparing the preoperative factors from
before and during the lockdown at the 3 pilot centers, a larger
proportion of patients who had undergone surgery during thee1092 www.SCIENCEDIRECT.com WORLD NElockdown had had visual compromise preoperatively compared
with those treated before the lockdown (P  0.01; Table 2).
Most of the tumors were pituitary adenomas (n ¼ 88 of 124;
71%), and most of these were macroadenomas (n ¼ 82 of 88;
93%). Of the 124 tumors, 63 were nonfunctioning pituitary ade-
nomas (51%). Of these 63 tumors, 62 were macroadenomas (98%).
Of the 25 functioning pituitary adenomas (20% of the 124 tumors),
20 were macroadenomas (20 of 25; 80%). Of the patients with a
functioning pituitary adenoma, 20 had had either Cushing disease
(n ¼ 10; 40%) or acromegaly/gigantism (n ¼ 10; 40%). The
remaining 36 pathological entities (29%) were 1 cm in size. The
characteristics of the remaining tumors are presented in Table 3.COVID-19 Screening Preoperatively
Preoperatively, 2 of the 124 patients (2%) had presented with
symptoms associated with COVID-19: 1 with a new cough and 1
with shortness of breath. Neither of these patients had tested
positive for COVID-19 when screened and both had eventually
undergone endoscopic surgery with the TSA—1 patient after 2
weeks self-isolation and negative swab results and 1 after
computed tomography of the thorax and swab testing were
negative (without isolation owing to clinical urgency). Of the 124
patients, 116 (94%) had undergone COVID-19 testing preopera-
tively (TSA, 95 of 102 [93%]; EEA, 21 of 22 [95%]). Eight patients
had not undergone COVID-19 testing preoperatively, usually
because of clinical urgency and the lack of rapid testing facilities at
the time (TSA, 7 of 102 [7%]; EEA, 1 of 22 [5%]). Of the patients
who had undergone screening, a swab test was used for all 116
(100%), with 1 patient also screened using computed tomographyUROSURGERY, https://doi.org/10.1016/j.wneu.2020.12.169
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positive for COVID-19 via the swab test preoperatively. The patient
who had tested positive (a 52-year-old man) underwent self-
isolation for 2 weeks and re-screening preoperatively. He subse-
quently had an endoscopic TSA for pituitary macroadenoma
resection after a re-screening swab test result was negative. The
swab types used were examined at the initial pilot centers (n ¼ 4)
and were either RNA polymerase chain reaction tests (n ¼ 2 of 4)
or RNA transcription-mediated amplification tests (n ¼ 2 of 4).Operation Characteristics
Most of the operations (n ¼ 47 of 124; 38%) were performed in July
(Figure 1). The median caseload during the pandemic was 44.8%
(interquartile range, 39.4%e49.3%) of the usual operative volume
when compared with the caseload during the same period in 2019
at selected core pilot centers (n ¼ 3).
Most of the cases had used the TSA (n ¼ 102 of 124; 82%). Of
the 102 TSA cases, 91 were performed endoscopically (89%) and 11
microscopically (11%). Also, of the 102 TSA cases, 92 were the
primary surgery (90%). The most common pathological entities
treated using the TSA included nonfunctioning pituitary ade-
nomas (n ¼ 61), functioning pituitary adenomas (n ¼ 24), and
craniopharyngiomas (n ¼ 4; Table 3). The EEA was used for 22 of




Median age (range) 52.
Visual loss
Anterior pituitary deficiency requiring hydrocortisone
Posterior pituitary deficiency requiring desmopressin
Tumor size >1 cm in diameter
Operative time (minutes)
Median (range) 83
Median TSA (range) 80
Median EEA (range) 151
Postoperative
Median length of stay (days; range) 4
General complications
CSF rhinorrhea (biochemically confirmed or requiring surgery)
CSF rhinorrhea requiring surgeryx
COVID-19, coronavirus disease 2019; TSA, transsphenoidal approach; EEA, expanded endonasal
*Mann-Whitney U test.
yFisher's exact test.
zVisual loss was a significantly more common complaint for patients presenting during the pand
xCSF diversion or direct repair.
WORLD NEUROSURGERY 149: e1090-e1097, MAY 2021treated using the EEA included craniopharyngiomas (n ¼ 9),
meningiomas (n ¼ 2), chordomas (n ¼ 2), and nonfunctioning
pituitary adenomas (n ¼ 2; Table 3). Of the 22 EEA cases, 20
were the primary surgery (91%).
The operating room staff involved in the 124 operations had
worn a range of PPE. The PPE used included surgical face masks
(TSA, 2 of 102 [2%]; EEA, 0 of 22 [0%]), FFP3 masks (TSA, 82 of
102 [80%]; EEA, 17 of 22 [77%]), powered hood respirators (TSA,
45 of 102 [44%]; EEA, 10 of 22 [45%]), eyeglasses (TSA, 59 of 102
[58%]; EEA, 15 of 22 [68%]), face shields (TSA, 47 of 102 [46%];
EEA, 10 of 22 [45%]), standard surgical gowns (TSA, 59 of 102
[58%]; EEA, 12 of 22 [55%]), double surgical gowns (TSA, 2 of 102
[2%]; EEA, 0 of 22 [0%]), and reinforced surgical gowns (TSA, 26
of 102 [25%]; EEA, 5 of 22 [23%]). Additional measures to reduce
the risk of airborne transmission are listed in Table 4.Postoperative Complications and Screening
The median length of patient stay was 4 days (range, 1e32 days)
for the entire group and was 3.5 days (range, 1e32 days) for the
TSA group and 7 days (range, 1e20 days) for the EEA group.
Overall, 28 of the 124 patients (23%) had experienced post-
operative complications (TSA, 19 of 102 [19%]; EEA, 9 of 22
[41%]). The most common complications were diabetes insipidus
(TSA, 7 of 102 [7%]; EEA, 4 of 22 [18%]), postoperative CSFomes at 3 Centers Before and During COVID-19
mic (n; % or Range) During Pandemic (n; % or Range) P Value
60 45
7 (18e84) 45 (8e82) 0.08*
21 (35) 32 (71) <0.01yz
12 (20) 12 (27) 0.49y
1 (2) 2 (4) 0.58y
49 (82) 41 (91) 0.26y
(35e200) 80 (35e302) 0.28*
(35e195) 76 (35e230) 0.78*
(83e200) 259 (137e302) 0.21*
(1e20) 5 (1e20) 0.18*
10 (17) 15 (33) 0.06y
3 (5) 4 (9) 0.46y
2 (3) 3 (7) 0.65y
approach; CSF, cerebrospinal fluid.
emic compared with before the pandemic.
www.journals.elsevier.com/world-neurosurgery e1093
Table 3. Tumor Type Stratified by Surgical Approach
Tumor Type TSA (n) EEA (n) Total (n)
Nonfunctioning pituitary adenoma 61 2 63
Functioning pituitary adenoma 24 1 25
Craniopharyngioma 4 9 13
Apoplexy 2 1 3
Rathke's cleft cyst 3 0 3
Chordoma 0 2 2
Cystic lesion (unspecified) 0 2 2
Meningioma 0 2 2
Arachnoid cyst 1 0 1
Germinoma 1 0 1
Hypophysitis 1 0 1
Melanoma metastasis 1 0 1
Meningoencephalocele 0 1 1
Mucinous gland 1 0 1
Prostate metastasis 1 0 1
Sinonasal carcinoma 0 1 1
Sinonasal endocrine tumor 1 0 1
Squamous cell carcinoma 0 1 1
Undefined neuroendocrine tumor 1 0 1
TSA, transsphenoidal approach; EEA, expanded endonasal approach.
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SOHAM BANDYOPADHYAY ET AL. CRANIAL COVIDrhinorrhea (TSA, 4 of 102 [4%]; EEA, 2 of 22 [9%]), and syndrome
of inappropriate antidiuretic hormone secretion (TSA, 4 of 102
[4%]; EEA, 1 of 22 [5%]). Other complications that had occurred
in the TSA group included residual disease, meningitis, sellar
abscess, unspecified hyponatremia, and mono-ocular blindness in
1 patient each (1%). The other complications that had occurred in
the EEA group included residual disease in 2 (9%) and unspecified
hyponatremia in 1 (5%). None of the 124 patients had died within
30 days postoperatively. The 1 patient with a recent history of
COVID-19 infection had had transient diabetes insipidus post-
operatively but no concerns for postoperative COVID-19 infection
or respiratory compromise. No significant differences were found
in postoperative outcomes when comparing the postoperative
outcomes before and during the lockdown at the 3 pilot centers
(Table 2).
Of the 124 patients, COVID-19 data at 30 days postoperatively
were available for 114 patients (92%). Postoperatively, 1 patient
(0.9%) had presented with symptoms associated with COVID-19: a
new cough. This patient had not tested positive for COVID-19
when screened. Of the 124 patients, 19 (15%) had undergone
COVID-19 screening within 30 days postoperatively (TSA, 11 of 102
[11%]; EEA, 8 of 22 [36%]). All 19 patients had undergone
screening using the swab test, and none had tested positive for
COVID-19. Data on the staff involved in surgery were available for
48 cases only. None of the staff had tested positive for COVID-19
within 30 days postoperatively.e1094 www.SCIENCEDIRECT.com WORLD NEDISCUSSION
Principal Findings
To the best of our knowledge, the present study is the first
multicenter study reporting data of contemporaneous endonasal
skull base operative practice during the COVID-19 pandemic. As
expected, the operative caseload was lowest at the peak of the
pandemic (March) and increased over time as operative protocols
were established and infection rates reduced. Most of these
endonasal neurosurgical cases were for pituitary adenoma (n ¼ 88
of 124 [71%]), and most patients were symptomatic preoperatively:
visual loss in 83 of 121 patients (69%), anterior pituitary deficiency
requiring hydrocortisone in 30 of 124 patients (24%), and/or
posterior pituitary deficiency requiring desmopressin in 5 patients
(4%). The most common approach used was the TSA (n ¼ 102 of
124; 82%). The operating room staff involved in these operations
adhered to international guidance by wearing at least level 2 PPE.12
Considerable heterogeneity was present in the PPE worn; however,
the PPE items worn in most cases were FFP3 masks (n ¼ 99 of 124;
80%) and eyeglasses (n ¼ 74 of 124; 60%). Adaptations to surgical
techniques included minimizing drilling, draping modifications,
and using nasal iodine wash.
At 30 days postoperatively, no evidence was found of COVID-19
infection (no symptoms and no positive test results) in our cohort
and no mortality had occured. One of the 116 patients had tested
positive for COVID-19 preoperatively and was isolated for 2 weeks,
with negative swab screening results before the patient underwent
surgery. This patient had developed transient diabetes insipidus
postoperatively; however no other complications had been
reported at 30 days postoperatively.
Findings in the Context of the Reported Data
Few studies have provided data on patients who have undergone
pituitary surgery during the COVID-19 pandemic. One case report
from Wuhan, China, described a patient developing COVID-19
within the first week after endoscopic endonasal pituitary
surgery. However, the use of a preoperative swab screening test
was not reported; thus, it was unclear whether the patient had had
COVID-19 preoperatively or had developed a postoperative
infection.19 Additionally, a case series from Cambridge, United
Kingdom, reported that none of 9 consecutive patients who had
undergone pituitary surgery or skull base surgery from March 30
to April 28, 2020, had contracted COVID-19 after the adoption
of a risk-mitigation protocol.12,18 Similar risk-mitigation strategies
were subsequently advocated by the Professional Education
Committee of the Pituitary Society. The results from our interna-
tional, multicenter study support the findings of the latter study,
because we did not find a greater risk to patients of acquiring
COVID-19 if they underwent endonasal surgery during the
pandemic. Our results also suggest that a standardized,
risk-mitigation strategy that accounts for earlier guidance might
allow for normalization of activity. Our results join an increasing
body of data showing that surgery is safe for patients with negative
SARS-CoV-2 test results preoperatively in a COVID-19efree sur-
gical pathway.24,25 The preoperative swab tests used in our series
were RNA polymerase chain reaction and transcription-mediated
amplification via nasopharyngeal swabs. The use of a single
swab is estimated to have a sensitivity of 70% and specificity ofUROSURGERY, https://doi.org/10.1016/j.wneu.2020.12.169
Figure 1. Bar graph showing the number of operations
per month with an overlay of the number of
coronavirus disease 2019 (COVID-19) cases in the
United Kingdom during the study period (data extracted
from the Public Health England database). No
operations were reported from March 23 to March
31, 2020.
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symptoms and disease prevalence.12,26,27 However, the resumption
of full elective workloads will depend on wider national and
international factors that protect patients from becoming
infected with SARS-CoV-2 and, thereby, avoid delays in surgery.
The noneCOVID-19 morbidity of patients with pituitary pathology
is an increasing concern, and our results could
help alleviate concerns about performing surgery during the
pandemic.Study Limitations
The present study had several limitations, which require a
tempered assessment of the findings. Firstly, because of the
reduced caseloads aimed at mitigating the effects of COVID-19, we
had a moderate sample size, especially with respect to EEA. Owing
to the recency of cases and the urgency to inform policymakers
about the risks to surgical patients, the follow-up period was
limited to the 30-day postoperative period. In addition, because
the present study was a prospective cohort study, the data points
were purely observational and across the context of multiple
centers. Also, owing to the observational nature, not all patients
had been screened postoperatively for COVID-19, and we were
reliant on these patients self-reporting any COVID-19 symptoms if
and when they had developed. Similarly, robust and consistent
data regarding the symptoms or infection rates of the surgical
team were lacking. The most significant limitation was the paucity
of baseline data to compare against the postoperative findings.
The prepandemic dataset used in the present study for limited
comparative analysis was not consecutive and was small in size.
The main CRANIAL study is ongoing and should provide the
baseline data with which to correlate our findings once the study
has been completed.21WORLD NEUROSURGERY 149: e1090-e1097, MAY 2021CONCLUSIONS
As operative protocols were established and infection rates
reduced, the number of endonasal operations increased. Guide-
lines reported by the Professional Education Committee of the
Pituitary Society were followed. No postoperative COVID-19
infections occurred; therefore, the patients who had undergone
surgery had not experienced any COVID-19erelated morbidity or
mortality. This suggests that a risk mitigation approach can enable
timely pituitary surgery to continue safely during the COVID-19
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Instillation of 0.3 mL of 0.5% PVP-I solution for skin and mucous membranes
in each nostril
Change from fluoroscopy to Stealth* to decrease movement of equipment
through multiple operating rooms
Minimization of bone drilling
Postoperative
Nasal packing avoided whenever possible
Most operating room staff not present during extubation
COVID-19, coronavirus disease 2019; PVP-I, povidone-iodine.
*StealthStation, Medtronic, Dublin, Ireland.
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